3. Merck & Co. Inc. (NYSE:MRK)
Number of Hedge Fund Holders — 101
Keytruda Remains Powerful While the Next Oncology Wave Takes Shape
Merck & Co., Inc. (NYSE: MRK) reported third-quarter worldwide sales of approximately $18.1 billion on October 29, up 5% from a year earlier. Combined Keytruda and Keytruda Qlex sales reached $8.6 billion, increasing 6%, with the subcutaneous Qlex formulation contributing $830 million. That makes the franchise both a formidable commercial asset and a concentration issue: a treatment family producing such a large share of revenue gives investors a clear reason to examine what comes next. For those evaluating immunotherapy stocks, current demand is important, but the durability of the earnings stream matters just as much.
Recent pipeline developments provide evidence of the company’s efforts to broaden its oncology portfolio. At the ESMO congress, management highlighted pivotal results for antibody-drug conjugate sacituzumab tirumotecan, or sac-TMT, in advanced or recurrent endometrial cancer. The FDA accepted an application based on those findings for Priority Review. The company also presented Phase 3 results involving individualized cancer vaccine candidate intismeran autogene combined with Keytruda as adjuvant treatment in resected melanoma. Chief Executive Officer Robert Davis said, “Our science-led strategy is transforming our business.” These programs offer additional development paths, although their regulatory and commercial prospects must be assessed individually.
The commercial challenge is to build enough durable revenue outside the existing flagship franchise before its patent protection becomes less secure. Welireg offers one example of an additional oncology product already contributing sales, with quarterly revenue reaching $307 million. Nevertheless, a broader pipeline does not translate immediately into a broader earnings base. Trials, regulatory reviews, manufacturing, and market access can stretch the timetable between positive data and meaningful profit. Investors should therefore compare the scale and timing of prospective launches with the revenue they may eventually need to replace. Pipeline diversification is most valuable when it arrives on time and at a reasonable cost.
Ranking rationale — Merck & Co., Inc. (NYSE: MRK) ranks third with 101 hedge fund holders. Its leading immunotherapy franchise, emerging oncology products, and late-stage pipeline support the position, while reliance on Keytruda makes the timing and commercial success of newer treatments especially important.
